More ImpediMed Limited news
ImpediMed LimitedASX: IPD

L-Dex Suggested as a New Standard of Care

Aug 23, 2018 at 11:09 PM EDT · Issued by ImpediMed Limited

Filed with ASX · Aug 23, 2018 at 11:09 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/l-dex-suggested-as-a-new-standard-of-care

Watch ImpediMed's latest call↗ImpediMed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of ImpediMed (ASX:IPD) Q1 2027 Earnings Call↗

ImpediMed Limited on 6ix

Earlier from ImpediMed

  • PREVENT Trial Results Published - Outstanding Initial DataAug 22, 2018
  • Appendix 4C - Quarter ended 30 June 2018Jul 22, 2018
  • Appendix 4C - Quarter ended 31 March 2018Apr 25, 2018
  • Interim Results of PREVENT TrialApr 19, 2018
  • US FDA 510(k) Clearance for Bilateral Lymphoedema AssessmentApr 17, 2018

Later from ImpediMed

  • Response to ASX Aware QueryAug 24, 2018
  • S&P DJI Announces September 2018 Quarterly RebalanceSep 6, 2018
  • ImpediMed Completes Asset Sale of XiTRON Technologies, Inc.Oct 11, 2018
  • Appendix 4C - Quarter ended 30 September 2018Oct 16, 2018
  • Ascension National Purchasing Agreement ReceivedJan 16, 2019
All ImpediMed news releases↗

Follow ImpediMed into a list and get an email when it puts out news.

Follow ImpediMed
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer